Becton Dickinson and (BDX) Earnings Date & Reports

Key Takeaways

• Revenue surpassed expectations: BD reported fiscal Q3 2026 revenue of $4.98 billion, exceeding the consensus estimate of $4.89 billion and rising 5.4% year over year on a reported basis.
• Adjusted EPS beat forecasts: Adjusted diluted earnings per share (EPS) came in at $3.23, topping analyst estimates of approximately $3.14 and growing 4.9% compared to the prior-year period.
• All four business segments posted growth: Each of BD's newly reorganized segments — Medical Essentials, Connected Care, BioPharma Systems, and Interventional — delivered currency-neutral revenue gains ranging from 3.2% to 5.5%.
• Full-year profit guidance raised: Management narrowed and raised its fiscal 2026 adjusted EPS outlook to $12.62–$12.72, up from the prior range of $12.52–$12.72, reflecting confidence in sustained momentum.
• Free cash flow surged: Year-to-date free cash flow (FCF) jumped 44.6% to $1.73 billion, driven by improved working capital management and lower non-operational cash outflows.
• Margin headwinds from tariffs persisted: Adjusted gross margin contracted 100 basis points year over year to 54.3%, with approximately 110 basis points of compression attributed to tariff-related costs.

Earnings Context and Why It Matters

Becton, Dickinson and Company's fiscal third quarter 2026 results, released on August 6, 2026, represented a milestone for the medical technology giant. The quarter marked the first full reporting period as "New BD" following the February 2026 separation of its Biosciences and Diagnostic Solutions business, which was combined with Waters Corporation. This transformative move recast BD as a more focused, pure-play MedTech company organized around four operating segments. The earnings report therefore served as an important early test of whether the streamlined corporate structure could translate into improved operational execution and financial performance. With the healthcare sector facing persistent tariff pressures, mixed international demand signals, and evolving regulatory dynamics, investors were closely watching whether BD's repositioning would support sustained momentum through the remainder of fiscal 2026.

Reported Results

BD posted third quarter fiscal 2026 revenue of $4.98 billion, representing 5.4% growth as reported and 4.4% growth on a foreign-currency-neutral (FXN) basis. The top-line result exceeded Wall Street's consensus estimate of approximately $4.89 billion by roughly $93 million, or about 1.8%. On the bottom line, GAAP diluted EPS from continuing operations was $1.64, compared to $1.57 in the same quarter a year ago. After adjusting for purchase accounting charges, restructuring costs, and other non-recurring items, adjusted diluted EPS rose to $3.23, a 4.9% year-over-year increase that beat the consensus forecast of $3.14 by approximately $0.09 per share.

Segment-level performance was broad-based. Medical Essentials generated $1.675 billion in revenue with 3.2% FXN growth, supported by strength in U.S. Vascular Access Management and the BD Vacutainer specimen collection portfolio. Connected Care delivered $1.224 billion, up 4.4% FXN, benefiting from double-digit growth in dispensing systems and continued market share gains with the BD Alaris infusion platform. BioPharma Systems recorded $670 million, a 5.2% FXN increase, fueled by double-digit expansion in biologics and GLP-1 (glucagon-like peptide-1) drug delivery programs. Interventional achieved $1.414 billion, up 5.5% FXN, driven by its peripheral intervention, urology, and surgery portfolios.

Geographically, U.S. revenue rose 6.9% to $3.08 billion, while international revenue grew a more modest 0.6% on an FXN basis to $1.90 billion, reflecting divergent regional demand conditions. Year-to-date operating cash flow from continuing operations increased 33.3% to $2.10 billion, and free cash flow surged 44.6% to $1.73 billion.

AI Screener

For investors seeking to identify opportunities across the healthcare and MedTech landscape, Tickeron's AI Screener offers a powerful AI-driven stock and ETF discovery platform. The tool enables users to filter thousands of securities using customizable criteria such as industry classification, market capitalization, technical indicators, price patterns, volatility metrics, and AI-generated trading signals. By surfacing stocks with specific technical and fundamental characteristics — including breakout candidates, trend-following setups, and oversold opportunities — the AI Screener helps traders and investors scan the market more efficiently than manual research alone. Explore the screener to uncover actionable ideas tailored to your strategy.

Market Reaction and Investor Sentiment

BD shares rose approximately 2.5% to 3.8% in pre-market trading on August 6, 2026, following the release, reaching levels around $175 to $177. The positive initial reaction reflected investor approval of the across-the-board earnings beat, the raised full-year profit guidance, and the strong free cash flow performance. Analysts noted that the quarter demonstrated disciplined execution across BD's newly focused portfolio, with over 90% of the business delivering high-single-digit revenue growth. However, the stock had declined roughly 12.1% year to date as of the earnings release, compared to the S&P 500's gain of approximately 12.8%, underscoring broader market caution around the medical device sector. Sentiment heading into the report had been mixed, with some analysts highlighting tariff exposure and sluggish international growth as potential headwinds. The beat and guidance raise provided a measure of reassurance, though sustained re-rating likely depends on consistent margin improvement and cash generation in the quarters ahead.

Forward Outlook and Key Factors to Monitor

Looking ahead, BD's updated fiscal 2026 guidance signals continued confidence. Management now expects revenue growth toward the high end of its low-single-digit range on a reported basis, with foreign exchange expected to contribute a tailwind of approximately 100 basis points. The adjusted diluted EPS forecast was narrowed and raised at the midpoint to $12.62–$12.72, implying fourth-quarter adjusted EPS of roughly $4.03 to $4.13 — a notable step-up from the prior-year period.

Several factors will shape BD's trajectory through the remainder of fiscal 2026 and into 2027. Tariff-related margin pressure remains a central concern. In the third quarter, tariffs accounted for roughly 110 basis points of the 130-basis-point decline in adjusted operating margin, to 24.9%. Investors will be watching whether productivity gains under the company's "BD Excellence" program can continue offsetting these external cost headwinds. The international business, which posted only 0.6% FXN growth in the quarter, also warrants monitoring, particularly given headwinds in China related to volume-based procurement policies and broader macroeconomic softness.

On the positive side, BD's cash generation story has strengthened materially. The 44.6% surge in year-to-date free cash flow was driven by improved working capital management, debt reduction of $2.7 billion year to date, and $2.25 billion in share repurchases. The company also received a $3.86 billion distribution from the spun-off entity. Capital allocation discipline, including progress toward BD's long-term net leverage target of 2.5x (from 2.9x at quarter-end), will be a key area of investor focus. Lastly, innovation catalysts — including new product launches in advanced patient monitoring, continued GLP-1 program expansion in BioPharma Systems, and Alaris infusion system market share gains — provide potential tailwinds that could drive incremental growth in coming quarters.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations